Kazakhstan is increasing its pharmaceutical
production. State support for investors has enabled the localization of innovative
drug manufacturing in the country, as well as technology transfer and personnel
training. To date, 90 long-term contracts have been signed with 34 companies
for the production of approximately 2,500 medicines and medical devices. The
country has established strong partnerships with leading global pharmaceutical
companies such as Pfizer, Roche, and AstraZeneca. Notably, AstraZeneca has
invested $5 million in drug production at Kazakh sites, with total investments
projected to reach about $40 million by 2030. The company plans to release its
first batch of products within a month. This was announced during a meeting of
the Investment Climate Improvement Council, chaired by Kazakh Prime Minister
Olzhas Bektenov and attended by representatives of foreign embassies, the
American Chamber of Commerce, and regional directors of international
companies. According to them, Kazakhstan has the potential to become a
technological production hub in the region.
«In his address to the people of Kazakhstan,
President Kassym-Jomart Tokayev stressed the need to implement comprehensive
measures to strengthen our nation’s health. Given the importance of this task,
the government has been taking active steps to enhance the national healthcare
system. The government of Kazakhstan aims to increase the volume of investment,
localize production and create high-value added clusters with the participation
of investors,» Bektenov noted.
«What makes Kazakhstan particularly attractive
is its competent and meticulous approach to selecting investors and supporting
them. In terms of investor support, the investment promotion agency Kazakh
Invest is probably the best in the Eurasian region. It provides full support
from start to finish, offering highly competent and qualified advice. They
fully assist with conducting negotiations and preparing all the documents
necessary for submitting an application for an investment agreement,» said Dmitry
Zanchev, President of GE Healthcare in Central Asia.
Related Articles
